NextGen geneCore Paradigm Comprehensive 22C3 Panel
NextGen geneCore Paradigm Comprehensive 22C3 Panel** Price
Brief Details
What Is a NextGen geneCore Paradigm Comprehensive 22C3 Panel?
The NextGen geneCore Paradigm Comprehensive 22C3 Panel is an advanced molecular diagnostic test that combines next-generation sequencing with PD-L1 immunohistochemistry testing. This comprehensive panel is performed on tumour tissue samples to identify genetic mutations and protein expressions that can guide personalised cancer treatment decisions.
The test helps detect actionable genetic mutations in solid tumours and measures PD-L1 protein expression, enabling doctors to select the most effective targeted therapies and immunotherapy options for each patient.
What Does the NextGen geneCore Paradigm Comprehensive 22C3 Panel Measure?
The Core Paradigm Comprehensive 22C3 Panel provides crucial information for precision oncology by measuring:
- Genetic mutations across 553 cancer-related genes that may respond to targeted therapies
- PD-L1 protein expression levels using the 22C3 antibody, which predicts immunotherapy response
- Microsatellite instability status for prognosis assessment
- Tumour mutation burden to guide treatment selection
- Actionable variants that can inform therapeutic decisions
NextGen geneCore Paradigm Comprehensive 22C3 Panel: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen geneCore Paradigm Comprehensive 22C3 Panel?
This test is ordered after a cancer diagnosis, not based on symptoms. However, the original symptoms that led to the cancer diagnosis may include:
- Persistent cough or chest pain suggesting lung cancer
- Difficulty swallowing or unexplained weight loss indicates gastric or oesophageal cancer.
- Abnormal vaginal bleeding pointing to cervical cancer
- Lumps in the breast suggesting triple-negative breast cancer
- Chronic bladder problems or blood in urine indicate urothelial carcinoma.
Who Should Get a NextGen geneCore Paradigm Comprehensive 22C3 Panel?
This specialised test is recommended for patients already diagnosed with specific types of cancer:
- Patients with non-small cell lung cancer seeking targeted therapy options
- Individuals diagnosed with gastric cancer are considering immunotherapy.
- Patients with cervical cancer requiring treatment planning
- Those with triple-negative breast cancer who need personalised treatment approaches
- Patients with head and neck cancers exploring precision oncology options
Why Is the NextGen geneCore Paradigm Comprehensive 22C3 Panel Done?
This panel is performed to personalise cancer treatment by identifying specific genetic mutations and protein expressions that can guide the selection of targeted therapies and immunotherapy, leading to better treatment outcomes.
Importance of a NextGen geneCore Paradigm Comprehensive 22C3 Panel
This comprehensive panel represents a significant advancement in precision oncology, moving away from one-size-fits-all cancer treatments. By analysing hundreds of genetic markers alongside PD-L1 expression, it enables oncologists to make evidence-based treatment decisions tailored to each patient's unique tumour profile.
The test's clinical relevance extends beyond treatment selection. It helps predict treatment response, avoid ineffective therapies, and identify patients who may benefit from clinical trials. For patients with PD-L1-positive tumours, immunotherapy can offer significantly better outcomes than traditional chemotherapy, while genetic mutation analysis opens doors to targeted therapy options that may be more effective with fewer side effects.
NextGen geneCore Paradigm Comprehensive 22C3 Panel Booking & Reports – Metropolis Healthcare India
How to Book a NextGen geneCore Paradigm Comprehensive 22C3 Panel?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen geneCore Paradigm Comprehensive 22C3 Panel', choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen geneCore Paradigm Comprehensive 22C3 Panel Available Near You?
No, home sample collection is not applicable for the Core Paradigm Comprehensive 22C3 Panel. This specialised test requires tumour tissue samples collected through biopsy procedures, which are performed in clinical settings. However, Metropolis Healthcare offers convenient access to this specialised test through our network of NABL & CAP accredited laboratories. Our expert pathologists and advanced technology ensure accurate results that help guide your treatment decisions with confidence.
How Long Does It Take to Get a NextGen geneCore Paradigm Comprehensive 22C3 Panel Report?
Reports are usually available within 20 days once the sample reaches the pathology lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen geneCore Paradigm Comprehensive 22C3 Panel Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen geneCore Paradigm Comprehensive 22C3 Panel Results
What Your NextGen geneCore Paradigm Comprehensive 22C3 Panel Results May Indicate
Your comprehensive panel results will include detailed analysis across multiple parameters to guide your treatment decisions:
|
Parameters |
Reference Range/Status |
Positive/High Results |
Negative/Low Results |
|
PD-L1 Expression (22C3) |
Tumour Proportion Score (TPS) or Combined Positive Score (CPS) |
Higher scores suggest a better response to immunotherapy. |
Lower scores may indicate limited immunotherapy benefit. |
|
Actionable Mutations |
Present/Absent for each of 553 genes |
Mutations detected may indicate targeted therapy options. |
No actionable mutations found in tested genes. |
Conditions That May Affect NextGen geneCore Paradigm Comprehensive 22C3 Panel Accuracy
Several factors can influence the accuracy of your comprehensive panel results and should be discussed with your oncologist:
- Poor tissue quality or insufficient tumour content in the biopsy sample may affect test reliability.
- Previous chemotherapy or radiation treatment can alter tumour genetics and protein expression.
- Sample age and storage conditions may impact DNA and protein preservation.
- Tissue fixation methods and processing delays can affect molecular analysis quality.
- Tumour heterogeneity may mean results vary between different areas of the same tumour.
How Is a NextGen geneCore Paradigm Comprehensive 22C3 Panel Done?
The comprehensive panel involves sophisticated laboratory processes to analyse your tumour tissue sample:
- Your oncologist orders the test and provides tumour tissue from a biopsy or surgery.
- The tissue sample is processed into thin sections on slides for analysis.
- Next-generation sequencing technology analyses DNA from 553 cancer-related genes.
- Immunohistochemistry staining detects PD-L1 protein expression using the 22C3 antibody.
- Advanced bioinformatics software interprets the genetic and protein data.
- Expert molecular pathologists review and validate all results before reporting.
How Should You Prepare for a NextGen geneCore Paradigm Comprehensive 22C3 Panel?
Since this test uses previously collected tumour tissue, specific preparation steps are minimal:
- No fasting required: Your diet does not affect tissue-based molecular analysis.
- Provide complete medical history: Share details about previous treatments and medications with your oncologist.
- Gather previous reports: Bring histopathology and immunohistochemistry reports from your cancer diagnosis.
- Discuss current medications: Inform your doctor about all treatments you're currently receiving.
Diseases that a NextGen geneCore Paradigm Comprehensive 22C3 Panel Can Help Detect
This comprehensive panel provides treatment guidance for various solid tumour types:
- Non-small cell lung cancer with actionable mutations and PD-L1 expression analysis
- Gastric cancer requiring an immunotherapy eligibility assessment
- Cervical cancer with HPV-related molecular changes
- Triple-negative breast cancer needs targeted therapy identification
- Head and neck squamous cell carcinomas are suitable for precision treatment.
- Urothelial carcinoma with potential immunotherapy responses
NextGen geneCore Paradigm Comprehensive 22C3 Panel/Packages That You Can Book With Metropolis Healthcare
Related molecular diagnostic tests are available to complement your comprehensive cancer analysis:
|
Test/Package Name |
Purpose/Highlights |
|
Alternative PD-L1 testing method for immunotherapy eligibility |
|
|
Microsatellite Instability (MSI) Test/HNPCC/Lynch Syndrome, PCR |
Detects Lynch syndrome and guides immunotherapy decisions |
|
Identifies high-risk HPV types in cervical cancer cases |
|
|
Genetic testing for hereditary breast and ovarian cancer risk |
|
|
Measures overall genetic changes to predict immunotherapy response |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.